WASHINGTON — Vienna, Virginia-based biotechnology company Cel-Sci, currently running late-stage clinical trials with patients for its head and neck cancer treatment, watched its stock fall more than 30 percent in early Tuesday trading …
WTOP10mon
CEL-SCI Corporation (NYSE MKT: CVM) announced today that during its annual Shareholder’s Meeting on June 12, 2017, a 1-for-25 reverse split was authorized for its outstanding shares of common stock. CEL-SCI expects the split to be …
CEL-SCI Corporation (CVM) down -12.66 per cent in the past week, is under coverage of 1 analysts who collectively recommend a hold rating on stock. 1 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. …
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an …
AOL3y
That's a total unknown that simply can't be answered right now. Kite is arguably the better stock to own at the moment because of Axi-Cel's near-term commercial prospects. Agenus, after all, is still three to four years away from bringing …
* Cel-Sci Corp - a 1-for-25 reverse split was authorized for its outstanding shares of common stock Source text for Eikon: Further company coverage:
Cellcom Israel Ltd. engages in the provision of cellular communications services. It operates through two segments: Cellcom and Netvision. The Cellcom segment includes Cellcom Israel Ltd. and its subsidiaries. The Netvision segment …
Vienna, VA, June 12, 2017-- CEL-SCI Corporation (NYSE MKT: CVM) announced today that during its annual Shareholder's Meeting on June 12, 2017, a 1-for-25 reverse split was authorized for its outstanding shares of common …